
Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.